166 related articles for article (PubMed ID: 8439504)
1. Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate.
O'Rourke NP; McCloskey EV; Vasikaran S; Eyres K; Fern D; Kanis JA
Br J Cancer; 1993 Mar; 67(3):560-3. PubMed ID: 8439504
[TBL] [Abstract][Full Text] [Related]
2. Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
Plosker GL; Goa KL
Drugs; 1994 Jun; 47(6):945-82. PubMed ID: 7521833
[TBL] [Abstract][Full Text] [Related]
3. Treatment of malignant hypercalcaemia with aminohexane bisphosphonate (neridronate).
O'Rourke NP; McCloskey EV; Rosini S; Coleman RE; Kanis JA
Br J Cancer; 1994 May; 69(5):914-7. PubMed ID: 8180023
[TBL] [Abstract][Full Text] [Related]
4. Treatment of the hypercalcaemia of malignancy with intravenous clodronate.
Urwin GH; Yates AJ; Gray RE; Hamdy NA; McCloskey EV; Preston FE; Greaves M; Neil FE; Kanis JA
Bone; 1987; 8 Suppl 1():S43-51. PubMed ID: 2961354
[TBL] [Abstract][Full Text] [Related]
5. Treatment of hypercalcaemia of malignancy with clodronate.
Bonjour JP; Rizzoli R
Bone; 1991; 12 Suppl 1():S19-23. PubMed ID: 1835397
[TBL] [Abstract][Full Text] [Related]
6. Is there a dose response relationship for clodronate in the treatment of tumour induced hypercalcaemia?
Shah S; Hardy J; Rees E; Ling J; Gwilliam B; Davis C; Broadley K; A'Hern R
Br J Cancer; 2002 Apr; 86(8):1235-7. PubMed ID: 11953878
[TBL] [Abstract][Full Text] [Related]
7. Clodronate treatment in patients with malignancy-associated hypercalcemia.
Rastad J; Benson L; Johansson H; Knuutila M; Pettersson B; Wallfelt C; Akerström G; Ljunghall S
Acta Med Scand; 1987; 221(5):489-94. PubMed ID: 2955674
[TBL] [Abstract][Full Text] [Related]
8. Effect of a single infusion of alendronate in malignant hypercalcaemia: dose dependency and comparison with clodronate.
Rizzoli R; Buchs B; Bonjour JP
Int J Cancer; 1992 Mar; 50(5):706-12. PubMed ID: 1531972
[TBL] [Abstract][Full Text] [Related]
9. Clodronate as a single-dose intravenous infusion effectively provides short-term correction of malignant hypercalcemia.
Atula ST; Tähtelä RK; Nevalainen JI; Pylkkänen LH
Acta Oncol; 2003; 42(7):735-40. PubMed ID: 14690159
[TBL] [Abstract][Full Text] [Related]
10. Single dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcaemia of malignancy.
Morton AR; Cantrill JA; Craig AE; Howell A; Davies M; Anderson DC
Br Med J (Clin Res Ed); 1988 Mar; 296(6625):811-4. PubMed ID: 3130925
[TBL] [Abstract][Full Text] [Related]
11. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy.
Purohit OP; Radstone CR; Anthony C; Kanis JA; Coleman RE
Br J Cancer; 1995 Nov; 72(5):1289-93. PubMed ID: 7577484
[TBL] [Abstract][Full Text] [Related]
12. Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia.
Ralston SH; Gallacher SJ; Patel U; Dryburgh FJ; Fraser WD; Cowan RA; Boyle IT
Lancet; 1989 Nov; 2(8673):1180-2. PubMed ID: 2572902
[TBL] [Abstract][Full Text] [Related]
13. Safety of subcutaneous clodronate and efficacy in hypercalcemia of malignancy: a novel route of administration.
Roemer-Bécuwe C; Vigano A; Romano F; Neumann C; Hanson J; Quan HK; Walker P
J Pain Symptom Manage; 2003 Sep; 26(3):843-8. PubMed ID: 12967733
[TBL] [Abstract][Full Text] [Related]
14. Treatment of tumor hypercalcemia with clodronate.
Ziegler R; Scharla SH
Recent Results Cancer Res; 1989; 116():46-53. PubMed ID: 2527400
[TBL] [Abstract][Full Text] [Related]
15. Comparative effects of calcitonin and clodronate in hypercalcaemia.
Ljunghall S; Rastad J; Akerström G
Bone; 1987; 8 Suppl 1():S79-83. PubMed ID: 2961359
[TBL] [Abstract][Full Text] [Related]
16. Severe hypercalcaemia four months after acute oliguric renal failure--successful treatment with intravenous clodronate.
Crowe G; Spedding R; McCance DR; Rankin SJ; Atkinson AB
Ir J Med Sci; 1992 Jun; 161(6):414-6. PubMed ID: 1386845
[TBL] [Abstract][Full Text] [Related]
17. The use of dichloromethylene bisphosphonate and aminobutane bisphosphonate in hypercalcemia of malignancy.
Adami S; Bolzicco GP; Rizzo A; Salvagno G; Bertoldo F; Rossini M; Suppi R; Lo Cascio V
Bone Miner; 1987 Aug; 2(5):395-404. PubMed ID: 2975514
[TBL] [Abstract][Full Text] [Related]
18. Treatment with clodronate in patients with hypercalcemia secondary to malignancy.
Lind L; Wengle B; Ljunghall S
Ups J Med Sci; 1987; 92(3):259-63. PubMed ID: 2966487
[TBL] [Abstract][Full Text] [Related]
19. Comparison of pharmacokinetics of clodronate after single and repeated doses.
Ylitalo P; Holli K; Mönkkönen J; Elo HA; Juhakoski A; Liukko-Sipi S; Ylitalo R
Int J Clin Pharmacol Ther; 1999 Jun; 37(6):294-300. PubMed ID: 10395121
[TBL] [Abstract][Full Text] [Related]
20. Intravenous clodronate for the treatment of hypercalcaemia in breast cancer patients with bone metastases--a prospective randomised placebo-controlled multicentre study.
Rotstein S; Glas U; Eriksson M; Pfeiffer P; Hansen J; Söderqvist J; Bandmann U; Strid S
Eur J Cancer; 1992; 28A(4-5):890-3. PubMed ID: 1388038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
